News
KYNB
7.27
+4.15%
0.29
Kyntra Bio schedules second-quarter 2026 results conference call
PUBT · 1d ago
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
NASDAQ · 4d ago
Weekly Report: what happened at KYNB last week (0727-0731)?
Weekly Report · 4d ago
Weekly Report: what happened at KYNB last week (0720-0724)?
Weekly Report · 07/27 09:15
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 07/23 12:15
Weekly Report: what happened at KYNB last week (0713-0717)?
Weekly Report · 07/20 09:14
Weekly Report: what happened at KYNB last week (0706-0710)?
Weekly Report · 07/13 09:15
KYNTRA BIO INC <KYNB.O>: OPPENHEIMER INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35
Reuters · 07/07 12:18
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 07/07 10:50
Kyntra Bio Initiated at Outperform by Oppenheimer
Dow Jones · 07/07 09:41
Kyntra Bio Price Target Announced at $35.00/Share by Oppenheimer
Dow Jones · 07/07 09:41
Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35
Benzinga · 07/07 09:31
U.S. RESEARCH ROUNDUP- BlackRock, Eli Lilly, Goldman Sachs
Reuters · 07/07 07:38
Kyntra Bio initiated with an Outperform at Oppenheimer
TipRanks · 07/06 20:20
Weekly Report: what happened at KYNB last week (0629-0703)?
Weekly Report · 07/06 09:15
Weekly Report: what happened at KYNB last week (0622-0626)?
Weekly Report · 06/29 09:15
Jade Biosciences names Vir Biotech ex-CMO Mark Eisner to board
PUBT · 06/26 11:00
Weekly Report: what happened at KYNB last week (0615-0619)?
Weekly Report · 06/22 09:16
Kyntra Bio Shareholders Back Board, Pay and Auditor
TipRanks · 06/16 10:44
Kyntra Bio shareholders approved executive pay in advisory vote at annual meeting
PUBT · 06/16 10:02
More
Webull provides a variety of real-time KYNB stock news. You can receive the latest news about KYNTRA BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.